OPKO Health will report its financial results for Q4 and full year 2025 on February 26, 2026, followed by a conference call. The company has also expanded its partnership with Entera Bio to advance an oral long-acting PTH tablet for hypoparathyroidism treatment, marking the third successful program combining Entera's N-Tab platform with OPKO's protein chemistry capabilities.

OPKO Health and Entera Bio have expanded their collaboration to develop the first oral long-acting PTH analog for hypoparathyroidism treatment, aiming to file an IND application in late 2026. The companies will maintain equal 50/50 ownership and cost-sharing for this program. Additionally, they are advancing oral oxyntomodulin (dual GLP-1/glucagon analog) with Phase 1 injectable data expected by end of 2026. Steve Rubin from OPKO has joined Entera's board.

Entera Bio's CEO will participate in the Evercore ISI Healthcare Conference, highlighting the company's progress in developing oral peptide therapies for conditions like osteoporosis and hypoparathyroidism.

NextPlat Corp provides an update on its strategic progress across healthcare services, communications, and e-commerce channels, highlighting cost reduction efforts, new contracts, and technology investments aimed at driving growth and profitability.

Entera Bio reported better-than-expected Q2 2025 earnings with a GAAP EPS of $0.06, secured FDA regulatory concurrence for EB613's Phase 3 trial, and maintained a strong cash position of $18.8 million to support operations through mid-Q3 2026.

NextPlat's interim CEO David Phipps outlined strategic plans to improve healthcare and e-commerce divisions, focusing on operational efficiency, cost reduction, and exploring growth opportunities following the unexpected passing of former CEO Charles M. Fernandez.

OPKO Health, Inc. and Entera Bio Ltd. announced that OPKO's ModeX Therapeutics division has formed a Scientific Advisory Board with leaders in immunology and oncology drug development. Additionally, OPKO and Entera's first-in-class dual GLP-1/Glucagon tablet candidate for obesity and metabolic disorders has been selected for presentation at the ENDO 2025 Annual Meeting.

OPKO Health's subsidiary ModeX Therapeutics has formed a Scientific Advisory Board with renowned experts in immunology and oncology to provide guidance on the development of its multispecific antibody pipeline.

The smart inhalers market is experiencing significant growth, driven by the increasing incidence of respiratory diseases, technological advancements, and growing awareness of digital health solutions. North America is expected to dominate the market during the forecast period.

The Minimal Residual Disease (MRD) Testing Market is expected to grow at a CAGR of 11.18% from 2025 to 2030, driven by advancements in diagnostic technologies and the increasing focus on precision medicine and early relapse detection.

OPKO Health and Entera Bio have entered into a collaboration agreement to advance an oral GLP-1/Glucagon dual agonist tablet into clinical trials for the treatment of obesity and metabolic disorders.

ModeX Therapeutics, an OPKO Health company, has been awarded additional funding from BARDA to develop multispecific antibodies for SARS-CoV-2 and influenza. The funding will support preclinical and Phase 1 trials for these programs, which are based on ModeX's proprietary MSTAR technology.